Merck presented the results from a Phase III clinical study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Orlando, which demonstrated that in comparison to placebo, AIT substantially lowered the overall combined score that is ...

KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, today announced the initiation of two pivotal U.S. Phase III trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental (under the chin) fat.

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD).

Dr. Nicole Onetto, Deputy Director and Chief Scientific Officer of the Ontario Institute for Cancer Research (OICR), today announced the launch of an innovative Phase III clinical trial that aims to determine whether multi-parametric magnetic resonance imaging (MRI) coupled with transrectal ultrasound (TRUS) guided biopsy (called fusion technology) can accurately ...

A research team today announced the launch of a European large-scale clinical trial of Nilvadipine, an Alzheimer's disease drug developed at the Roskamp Institute in Sarasota.

This spring, Q1 Productions will host its Maximizing Clinical Operations in Phase I - III Studies Conference in pharmaceutical industry hub, Chicago, IL. As pharmaceutical companies' efforts in reducing time to product launch lie primarily in streamlining clinical research duration, they unfortunately find clinical trial delay is one of ...

OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with ...

AMAG Pharmaceuticals, Inc. today announced the completion of patient enrollment in the second of the company's two phase III studies that comprise its global registrational program for Feraheme (ferumoxytol) in patients with iron-deficiency anemia (IDA) who are not candidates for oral iron, regardless of the underlying cause.

Baxter International Inc. today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10%, for the treatment of mild to moderate Alzheimer's disease.

Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed.

CEL-SCI Corporation is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection) to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia.

MSD announced the results of their Phase III study of vorinostat at the 53rd Annual Meeting of the American Society of Hematology (ASH). Vorinostat, designed for treatment in patients with progressive multiple myeloma, has met its primary endpoint in a Phase III study for investigational use in combination with bortezomib ...